PTPRC and cancer: To avoid the concomitant pharmacological inhibition of TAK1 in immune cells, an additional experiment was carried out in which the CD45+ immune cells were first separated from the remaining cells (e.g. cancer cells, fibroblasts, etc.)(Fig. 5i, Supplementary Fig. 8, Supplementary Table 5).